CN108926561A - Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product - Google Patents
Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product Download PDFInfo
- Publication number
- CN108926561A CN108926561A CN201810461753.0A CN201810461753A CN108926561A CN 108926561 A CN108926561 A CN 108926561A CN 201810461753 A CN201810461753 A CN 201810461753A CN 108926561 A CN108926561 A CN 108926561A
- Authority
- CN
- China
- Prior art keywords
- jateorrhizine
- drug
- big health
- learning
- oriented products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of application of jateorrhizine or jateorrhizine pharmaceutically acceptable salt in the drug or the improvement big health-oriented products of learning and memory class of preparation senile dementia prevention and cure, and the drug or the improvement big health-oriented products of learning and memory class of a kind of senile dementia prevention and cure, the drug or big health-oriented products include jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt.The drug of senile dementia prevention and cure is prepared using the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt or improves the big health-oriented products of learning and memory class, with preferable bioactivity (inhibiting activity of acetylcholinesterase is high), simultaneously, side effect is smaller, has a good application prospect.
Description
Technical field
The invention belongs to pharmaceutical technology fields more particularly to a kind of jateorrhizine in prevention and treatment dementia or to improve memory class production
Application in product, and in particular to a kind of jateorrhizine or jateorrhizine pharmaceutically acceptable salt are old silly in preparation prevention and treatment
The drug of slow-witted disease improves the application in the big health-oriented products of learning and memory class and a kind of drug of senile dementia prevention and cure dementia
Or improve the big health-oriented products of learning and memory class.
Background technique
With the aggravation of population in the world aging, senile dementia have become ultimate challenge that global medical health faces it
One.According to statistics, the whole world about has more than 46,000,000 dementia patients, and will be increased with every 20 years speed to double.It is expected that extremely
The year two thousand thirty, global dementia patients will be up to 66,000,000 people, and the year two thousand fifty that arrives, this number will likely be more than 1.15 hundred million.2010 silly
Staying in burden on society cost caused by the whole world is about 604,000,000,000 dollars, has been more than the 1% of whole world GDP.And China existing 65
Year old or more elderly population 1.77 hundred million, be the maximum country of elderly population radix of the world, and the disease incidence of senile dementia rises year by year,
The dementia patients in the whole world about 20% live in China, this ratio will reach 30.4% in the year two thousand fifty, this undoubtedly also gives China
Medical and health care system and socio-economic development bring heavy burden, try to explore prevent and treat AD new method novel drugs compel in eyebrow
Eyelash.
The common clinical symptoms of senile dementia include：Cognitive disorder, memory disorders, time and spatial orientation ability obstacle,
Unsociable and eccentric indifferent, mental and behavioral disorders etc., and the death rate is very high, has become and is only second to painstaking effort cranial vascular disease and cancer
Disease leads to one of the three big reasons of the elderly's death.Since senile dementia technological invention mechanism is complicated, at present there is no good prevention and treatment medicines
Object.Acetylcholinesterase inhibitor be FDA it is the only approved treatment Alzheimer disease fiest-tire medication, mainly have galanthamine,
How neat more piperazines are, and there are the drugs such as huperzine in China, but these drug side-effects are stronger, expensive.
Dull-witted one line of clinic of prevention and treatment mainly uses the first-class drug of galanthamine, donepezil, huperzine at present.These medicines
Object is expensive, side effect is larger, and cannot delay dull-witted Development process.For at present there is no significant in efficacy, side effect compared with
Less, the status of the lower prevention and treatment anti-dementia agent of price is badly in need of researching and developing a kind of drug that can effectively prevent dementia.
Summary of the invention
It is old silly in preparation prevention and treatment that the purpose of the present invention is to provide a kind of new application-jateorrhizines of jateorrhizine
The drug of slow-witted disease or the application in the improvement big health-oriented products of learning and memory class, it is intended to which at present there is no significant in efficacy, side effects for solution
The problem of less, price lower prevention and treatment anti-dementia agent.
Another object of the present invention is to provide a kind of drug of senile dementia prevention and cure or improvement learning and memory class are strong greatly
Health product.
For achieving the above object, the technical solution adopted by the present invention is as follows：
One aspect of the present invention provides a kind of jateorrhizine or jateorrhizine pharmaceutically acceptable salt and prevents and treats in preparation
The drug of senile dementia or the application in the improvement big health-oriented products of learning and memory class.
One aspect of the present invention provides the drug or the improvement big health-oriented products of learning and memory class of a kind of senile dementia prevention and cure, institute
It states drug or big health-oriented products includes the active material of acetylcholine esterase inhibition activity, the active material includes calumba
Alkali and/or jateorrhizine pharmaceutically acceptable salt.
Jateorrhizine or jateorrhizine pharmaceutically acceptable salt provided by the invention prevents and treats senile dementia in preparation
The drug of disease or the application in the improvement big health-oriented products of learning and memory class, the jateorrhizine acetylcholine esterase inhibition activity
Higher, the active IC50 inhibited to acetylcholinesterase reaches 0.01ug/ml, and the prevention and treatment better than current FDA approval listing is silly
Slow-witted galanthamine, close to the fiest-tire medications such as how neat more piperazines are, it is silly to can be used for preventing and treating senile dementia, vascular dementia, mixed type
Various senile dementias and other kinds of cognition and the memory disorders such as slow-witted, and toxic side effect is smaller.In addition, the calumba
Alkali also has the function of certain antibacterial, anti-inflammatory, reduction blood lipid, prevention and treatment diabetes etc., has a good application prospect.It adopts
The drug of senile dementia prevention and cure is prepared with the jateorrhizine, jateorrhizine pharmaceutically acceptable salt or is improved learns
Practise the big health-oriented products of memory class or using the jateorrhizine, jateorrhizine pharmaceutically acceptable salt as anti-punish-old
The drug of dementia disease or when improving the active constituent of the big health-oriented products of learning and memory class, has preferable bioactivity (acetyl
Cholinesterase inhibition).In addition, the jateorrhizine is resourceful, jateorrhizine, jateorrhizine pharmaceutically may be used
The salt of receiving is used to prevent and treat the preparation of anti-dementia agent, can reduce the cost of medicine for senile dementia.
The drug of senile dementia prevention and cure provided by the invention improves the big health-oriented products of learning and memory class, the drug or
Big health-oriented products include the active material of acetylcholine esterase inhibition activity, the active material include jateorrhizine and/or
Jateorrhizine pharmaceutically acceptable salt.The jateorrhizine acetylcholine esterase inhibition activity is higher, to acetyl gallbladder
The active IC50 of alkali esterase inhibition reaches 0.01ug/ml, and the galanthamine dull-witted better than the prevention and treatment of current FDA approval listing connects
The fiest-tire medications such as how neat nearly more piperazines are, can be used for preventing and treating the various senile dementias such as senile dementia, vascular dementia, mixed dementia
Disease and other kinds of cognition and memory disorders, and toxic side effect is smaller.In addition, the jateorrhizine also has certain resist
It the effects of bacterium, anti-inflammatory, reduction blood lipid, prevention and treatment diabetes, has a good application prospect.With the jateorrhizine and/or non-
Continent menispermine pharmaceutically acceptable salt as senile dementia prevention and cure drug or improve learning and memory class big health-oriented products
When active constituent, have preferable bioactivity (inhibiting activity of acetylcholinesterase).In addition, the jateorrhizine resource is rich
Jateorrhizine is used to prevent and treat the preparation of anti-dementia agent by richness, can reduce the cost of prevention and treatment medicine for senile dementia.
Specific embodiment
In order to which technical problems, technical solutions and advantageous effects to be solved by the present invention are more clearly understood, below in conjunction with
Embodiment, the present invention will be described in further detail.It should be appreciated that specific embodiment described herein is only used to explain
The present invention does not limit the present invention.
In the description of the present invention, it is to be understood that, term " first ", " second " only describe purpose, and cannot understand
For indication or suggestion relative importance or implicitly indicate the quantity of indicated technical characteristic.Define as a result, " first ",
The feature of " second " can explicitly or implicitly include one or more of the features.In the description of the present invention, " more
It is a " it is meant that two or more, unless otherwise specifically defined.
It is anti-in preparation that the embodiment of the invention provides a kind of jateorrhizines or jateorrhizine pharmaceutically acceptable salt
It controls the drug of senile dementia or improves the application in the big health-oriented products of learning and memory class.
Jateorrhizine or jateorrhizine pharmaceutically acceptable salt provided in an embodiment of the present invention is preparing anti-punish-old
The drug or the application in the improvement big health-oriented products of learning and memory class, the jateorrhizine of dementia disease inhibit acetylcholine ester
Enzymatic activity is higher, and the active IC50 inhibited to acetylcholinesterase reaches 0.01ug/ml, better than current FDA approval listing
It prevents and treats dull-witted galanthamine, close to the fiest-tire medications such as how neat more piperazines are, can be used for preventing and treating senile dementia, vascular dementia, mixes
The various senile dementias such as mould assembly dementia and other kinds of cognition and memory disorders, and toxic side effect is smaller.In addition, described non-
Continent menispermine also has the function of certain antibacterial, anti-inflammatory, reduction blood lipid, prevention and treatment diabetes etc., has good application
Prospect.The drug of senile dementia prevention and cure is prepared using the jateorrhizine, jateorrhizine pharmaceutically acceptable salt
Or improves the big health-oriented products of learning and memory class or made with the jateorrhizine, jateorrhizine pharmaceutically acceptable salt
For the drug of senile dementia prevention and cure or when improving the active constituent of the big health-oriented products of learning and memory class, have preferable biology living
Property (inhibiting activity of acetylcholinesterase).In addition, the jateorrhizine is resourceful, by jateorrhizine, jateorrhizine
Pharmaceutically acceptable salt is used to prevent and treat the preparation of anti-dementia agent, can reduce the cost of medicine for senile dementia.
And the embodiment of the invention provides a kind of drug of senile dementia prevention and cure or improve the big health of learning and memory class
Product, the drug or big health-oriented products include the active material of acetylcholine esterase inhibition activity, and the active material includes
Jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt.
The drug of senile dementia prevention and cure provided in an embodiment of the present invention improves the big health-oriented products of learning and memory class, described
Drug or big health-oriented products include the active material of acetylcholine esterase inhibition activity, and the active material includes jateorrhizine
And/or jateorrhizine pharmaceutically acceptable salt.The jateorrhizine acetylcholine esterase inhibition activity is higher, to second
The active IC50 that acetylcholinesterase inhibits reaches 0.01ug/ml, the Garland dull-witted better than the prevention and treatment of current FDA approval listing he
It is quick, close to the fiest-tire medications such as how neat more piperazines are, it is various old to can be used for preventing and treating senile dementia, vascular dementia, mixed dementia etc.
Dementia disease and other kinds of cognition and memory disorders, and toxic side effect is smaller.In addition, the jateorrhizine also has one
Fixed antibacterial, the anti-inflammatory, effect that reduces blood lipid, prevention and treatment diabetes etc., have a good application prospect.It is anti-with the Africa
Own alkali and/or jateorrhizine pharmaceutically acceptable salt are big as the drug or improvement learning and memory class of senile dementia prevention and cure
When the active constituent of health-oriented products, have preferable bioactivity (inhibiting activity of acetylcholinesterase).In addition, the Africa is anti-
Own alkali is resourceful, and jateorrhizine is used to prevent and treat the preparation of anti-dementia agent, can reduce the cost of medicine for senile dementia.
In the embodiment of the present invention, as in the drug or the improvement big health-oriented products of learning and memory class of senile dementia prevention and cure
Active material, the jateorrhizine have the activity of preferable acetylcholine esterase inhibition, the suppression to acetylcholinesterase
System activity IC50 reaches 0.01ug/ml.
In the embodiment of the present invention, the jateorrhizine can be learned separately as the drug of senile dementia prevention and cure or improvement
Practise the active material in the big health-oriented products of memory class.Jateorrhizine pharmaceutically acceptable salt has anti-with the Africa simultaneously
The bioactivity of the own comparable acetylcholine esterase inhibition of base sheet, therefore equally can be separately as senile dementia prevention and cure
Active material in drug or the improvement big health-oriented products of learning and memory class.Certainly, the jateorrhizine and the calumba
Alkali pharmaceutically acceptable salt can be present in the drug of senile dementia prevention and cure collectively as active material or improve study note
Recall in the big health-oriented products of class.Significantly, since jateorrhizine and jateorrhizine pharmaceutically acceptable salt inhibit
The mechanism of action of acetylcholine esterase active is suitable with activity level, and (jateorrhizine, Africa are anti-for three kinds of situations described above
Own alkali pharmaceutically acceptable salt, jateorrhizine and jateorrhizine pharmaceutically acceptable salt) action principle as, because
This, hereinafter jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt (three kinds of situations) will be retouched as a whole
It states, is no longer separately illustrated.
Specifically, the jateorrhizine pharmaceutically acceptable salt is selected from jateorrhizine hydrochloride, jateorrhizine
At least one of citrate, calumba alkali phosphate, calumba alkali sulfate, jateorrhizine disulfate, but
It is without being limited thereto, other jateorrhizine pharmaceutically acceptable salts can be used for senile dementia prevention and cure of the present invention drug or
Improve in the big health-oriented products of learning and memory class.
As an implementation, made using the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt
For the drug of senile dementia prevention and cure or active material, that is, unique active material of the improvement big health-oriented products of learning and memory class, have
Acetylcholine esterase inhibition activity is imitated, the dull-witted drug effect of prevention and treatment is played.In terms of i.e. by the total weight of the active material for 100%,
The weight percentage of the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt is 100%.
Preferably, with the total weight of the drug or big health-oriented products for 100%, the jateorrhizine and/or Africa
The weight percentage of menispermine pharmaceutically acceptable salt is 0.05%-100%.It is suitable in the drug or big health-oriented products
Jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt weight percentage, it is ensured that jateorrhizine
Relative amount it is suitable, thus preferably play acetylcholinesterase inhibitory activity.Herein, it should be understood that can will be pure
Jateorrhizine monomer and/or jateorrhizine pharmaceutically acceptable salt are prepared into drug or big health-oriented products, can also incite somebody to action
Jateorrhizine monomer and/or jateorrhizine pharmaceutically acceptable salt, with do not have acetylcholine esterase inhibition activity
Compound together, is prepared into drug or big health-oriented products.The signified acetylcholine esterase inhibition that do not have of the embodiment of the present invention is lived
The compound of property includes but is not limited to auxiliary material.
As another embodiment, the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt can be with
Have together with the active material for preventing and treating dull-witted drug effect with other, collaboration plays acetylcholine esterase inhibition activity, as medicine group
It closes object and plays the dull-witted drug effect of prevention and treatment.
Preferably, with the total weight of the drug or big health-oriented products for 100%, the jateorrhizine and/or Africa
The weight percentage of menispermine pharmaceutically acceptable salt is 0.05%-100%.It is suitable in the drug or big health-oriented products
Jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt weight percentage, it is ensured that jateorrhizine
Relative amount is suitable, to preferably play the inhibitory activity of acetylcholinesterase.Herein, it should be understood that can will be pure non-
Continent menispermine monomer and/or jateorrhizine pharmaceutically acceptable salt and other active materials one with the dull-witted drug effect of prevention and treatment
It rises and is prepared into drug or big health-oriented products, it can also be pharmaceutically acceptable by jateorrhizine monomer and/or jateorrhizine
Salt has the active material for preventing and treating dull-witted drug effect and the compound one without acetylcholine esterase inhibition activity with other
It rises, is prepared into drug or big health-oriented products.
It is further preferred that being the jateorrhizine and/or Africa in terms of 100% by the total weight of the active material
The weight percentage of menispermine pharmaceutically acceptable salt is 0.5%-100%.Relative to existing known with inhibition
The active material galanthamine of acetylcholine esterase active, the jateorrhizine and/or jateorrhizine are pharmaceutically acceptable
The salt total weight that accounts for the active material weight percentage it is higher, the activity of acetylcholine esterase inhibition activity is got over
By force, dull-witted drug effect is prevented and treated to be more obvious.
As another embodiment, the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt can be with
It prevents and treats dull-witted drug effect with not having but can promote together with the component of the jateorrhizine acetylcholine esterase inhibition activity,
The dull-witted effect of prevention and treatment is played as drug or big health-oriented products ingredient.It on this basis, can also be by the jateorrhizine
And/or jateorrhizine pharmaceutically acceptable salt, there is the active material for preventing and treating dull-witted drug effect with other and do not have anti-
It controls dull-witted drug effect but the component of the jateorrhizine acetylcholine esterase inhibition activity can be promoted together, as drug or big
The collaboration of health-oriented products ingredient plays the dull-witted effect of prevention and treatment.
On the basis of above-mentioned three kinds of embodiments, it is preferred that the drug of senile dementia prevention and cure of the present invention changes
In the kind big health-oriented products of learning and memory class, the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt it is effective
Dosage is 1mg-3000mg/ days.In the embodiment of the present invention, the jateorrhizine and/or jateorrhizine are pharmaceutically acceptable
Salt be used to prevent and treat the galanthamine fiest-tire medication that dull-witted effective dose can be dull-witted lower than the prevention and treatment of current FDA approval listing,
As it can be seen that the drug using the jateorrhizine as active material, have effects that preferably to prevent and treat it is dull-witted, application prospect compared with
It is good.Preferably, when the effective dose of the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt is 5mg-
3000mg/ days.Specifically, when the effective dose mistake of the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt
When low, the effect of acetylcholine esterase inhibition activity is reduced, or even cannot play apparent acetylcholine esterase inhibition activity, is led
Jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt is caused to be crazy about as drug in use, not having apparent prevention and treatment
Slow-witted function and effect.When the effective dose of the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt is excessively high, meeting
There is gastrointestinal side effect etc..
Wherein, dull-witted effective dose is prevented and treated described in the embodiment of the present invention and refers to therapeutically effective amount, is referred to and is enough to individual
Show the amount of the compound of the present invention of benefit or clinical meaning.It will be understood to those of skill in the art that administration actual amount or
Dosage and administration time-histories will depend on the property and seriousness, age of treated subject and general of treated disease
Situation and administration mode etc..
As a preferred embodiment, the drug or the improvement big health-oriented products of learning and memory class of the senile dementia prevention and cure
In, including the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt, it further include coptisine, palmatine, barberry
At least one of alkali.The coptisine, palmatine, jamaicin all have the function of certain acetylcholine esterase inhibition activity
Effect, will be in the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt and coptisine, palmatine, jamaicin
At least one compound drug as senile dementia prevention and cure or when improving the active constituent of the big health-oriented products of learning and memory class, suppression
The bioactivity of acetylcholinesterase processed can be further strengthened, anti-acetylcholinesterase significant effect, can be used for old
The prevention and treatment of dementia.
As further preferred embodiments, the big health of drug or improvement learning and memory class of the senile dementia prevention and cure is produced
Product include jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin, i.e. Africa is anti-
Own alkali and/or jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin are dull-witted as the prevention and treatment simultaneously
Pharmaceutical composition in active material.Compared to jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt and Huang
Even alkali, palmatine, at least one of jamaicin are compound as drug or the active constituent of big health-oriented products, while using Africa
Menispermine and/or jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin are old silly as the prevention and treatment
The drug or the active constituent in the improvement big health-oriented products of learning and memory class, four kinds of active materials of slow-witted disease mutually cooperate with, have more
Add the drug effect of significant acetylcholine esterase inhibition.
Further, in described pharmaceutical composition, jateorrhizine and/or jateorrhizine are pharmaceutically acceptable
Salt, coptisine, palmatine, jamaicin weight ratio be (1-25):(1-25):(1-25):(1-25).Jateorrhizine and/or
Jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin content within the above range when, have more preferable
Synergistic effect.
When the drug or the improvement big health-oriented products of learning and memory class of the senile dementia prevention and cure include simultaneously calumba
When alkali and/or jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin, the drug or big health-oriented products
In, with the total weight of active material in the drug or big health-oriented products for 100%, the jateorrhizine and/or Africa are anti-
The weight percentage of own alkali pharmaceutically acceptable salt is 20%-50%, to play better acetylcholine esterase inhibition
Bioactivity, it is more significant to prevent and treat dull-witted effect.
On this basis, it is preferred that jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt, coptisine, bar
When the active constituent of Ma Ting, jamaicin pharmaceutical composition dull-witted as prevention and treatment simultaneously, the effective dose of active constituent is 5mg-
3000mg/ days.Due to jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt, coptisine, palmatine, jamaicin
Between mutual synergistic effect has occurred, therefore, as pharmaceutical composition in use, the effect of its acetylcholine esterase inhibition activity
Enhancing, under same active effect, the effective dose of pharmaceutical composition active constituent is reduced compared with the effective dose of activated monomer,
The effective dose of preferred active constituent is 20mg-1000mg/ days, it is further preferred that the effective dose of active constituent is
100mg-800mg/ days.
In the embodiment of the present invention, the drug of the senile dementia prevention and cure or improve the big health-oriented products of learning and memory class in addition to
May include active material (active constituent) in above-mentioned implementation situation outside, can also include pharmaceutically acceptable auxiliary material.It should
Pharmaceutically acceptable auxiliary material may include that can prevent and treat dull-witted drug with the embodiment of the present invention to close the one or more of object compatibility
It is silly that pharmaceutically acceptable carrier, solvent, excipient, buffer, stabilizer, adjuvant, prodrug and treatment can benefit from prevention and treatment
Stay or enhance the above-mentioned active other therapeutic agents of prevention and treatment dementia Chinese medicine composition.The not stringent limit of the concrete type of the auxiliary material
It is fixed, it can be selected according to Selective type, the finally formed dosage form etc. of specific active constituent, including but not limited to crystallite
Cellulose, lactose, crospovidone, magnesium stearate, glycerol, oleic acid, soybean oil etc..
It should be understood that above-mentioned each auxiliary material should be it is nontoxic, do not interfere or not damage the embodiment of the present invention above-mentioned anti-
Control the effect of dull-witted Chinese medicine composition.In addition, dull-witted drug or guarantor can be prevented and treated selected by the auxiliary material according to above-described embodiment
Health food is flexibly selected there are dosage form.
As a most preferred embodiment, described pharmaceutical composition pharmaceutically may be used by jateorrhizine and/or jateorrhizine
Salt, coptisine, palmatine, jamaicin and the pharmaceutically acceptable auxiliary material composition of receiving.
In the embodiment of the present invention, according to the drug of embodiments of the present invention senile dementia prevention and cure or improve learning and memory
The mode of administration of the big health-oriented products of class can flexibly select pharmaceutically acceptable auxiliary material and effective dose to prevent and treat dull-witted Chinese traditional medicine composition
Object is prepared into different dosage forms, such as mixture, capsule, tablet, pill, powder, pulvis, emulsion, gelling agent, dripping pill, slow controlled release
Any dosage form in preparation, liposome.Wherein, the tablet includes but is not limited to dispersible tablet.Certainly, the embodiment of the present invention prevents and treats
The drug of senile dementia or the dosage form for improving the big health-oriented products of learning and memory class are without being limited thereto, can also be pharmaceutically acceptable
Other dosage forms.
Therefore, the drug of senile dementia prevention and cure of the embodiment of the present invention or the improvement big health-oriented products of learning and memory class are due to containing
The active material for having the prevention and treatment described above of effective dose dull-witted, therefore, the medicine of senile dementia prevention and cure of the embodiment of the present invention
Object improves the big health-oriented products of learning and memory class with the dull-witted drug effect of apparent prevention and treatment, and long-term use has no toxic side effect, clinical suitable
Answering property is good.
The drug or the improvement big health-oriented products of learning and memory class of senile dementia prevention and cure described in the embodiment of the present invention can be single
Solely administration, if can also be administered in combination with other necessary compositions.
In the embodiment of the present invention, the dull-witted pharmaceutical composition of the prevention and treatment can be prepared using a variety of methods.Such as, it adopts
With chemically synthesized method, each compound is prepared respectively, is then compounded according to the ratio met the requirements, and the prevention and treatment is prepared
Dull-witted pharmaceutical composition；Active constituent source of the natural drug as pharmaceutical composition can also be used, to containing of the invention
Natural drug, medicinal material of embodiment aforementioned pharmaceutical compositions active material etc. carry out active constituent extraction with separate, will obtain
Each active material monomer compounded, prepare the dull-witted pharmaceutical composition of the prevention and treatment.Specifically, using extracting and separating
When method obtains the active material for preventing and treating dull-witted pharmaceutical composition described in the embodiment of the present invention, can according to following processes into
Row：
The medicinal material or medicine materical crude slice of active material ingredients containing the dull-witted pharmaceutical composition of prevention and treatment are extracted, Extraction solvent
Including water, ethyl alcohol, the mixture of ethanol water, the aqueous solution containing certain chemical acidic materials, then filters, is concentrated, is dry,
In, filtering includes the methods of the screen to filtrate, centrifugal filtration, and concentration includes reduced pressure, normal pressure concentration etc., and dry includes spraying do
It is dry, be dried under reduced pressure, the methods of forced air drying；Composition is obtained, is then passing through various chromatographic processes, including macroreticular resin, silicon
Different points of plastic column chromatography, gel chromatography, high speed adverse current chromatogram, preparation liquid phase, opposed polarity alumina column chromatography, polyamide chromatography etc.
One or several kinds combination from mode, prepares monomer jateorrhizine, coptisine, palmatine, jamaicin；Then these are non-
Continent menispermine, coptisine, palmatine, jamaicin or composition individually, at salt or different proportion combination are made various suitable
Suitable preparation.
For the coptis as traditional Chinese medicine, medicinal material, medicine materical crude slice and its extract are only used as heat-clearing and damp-drying drug, antibacterial anti-inflammatory raw material to make
With not yet finding its significant anti-acetylcholine cholinesterase effect, not thering is the application for being individually used for anti-senile dementia to go through
History.The embodiment of the present invention is preferably using the coptis as the active constituent for preventing and treating dull-witted pharmaceutical composition described in the embodiment of the present invention
Source prepares jateorrhizine, coptisine, palmatine, jamaicin monomer and combinations thereof using effective method, has significant
Anti-acetylcholinesterase effect, can be used for senile dementia prevention and treatment.
As a kind of specific preferred embodiment, prevention and treatment described in the embodiment of the present invention is obtained using extraction and isolated method
The method of the active material of dull-witted pharmaceutical composition is：Rhizoma Coptidis is provided, by taking 5Kg medicinal material as an example, is crushed after net system processing
At coarse powder, the ethyl alcohol of 50%-90% is added, impregnates 0-120min, is heated to reflux 2 times, it is 1.0-3.0 hours each；It is concentrated under reduced pressure,
It obtains, using macroreticular resin 2kg, filling column containing jateorrhizine, coptisine, palmatine, jamaicin thick paste 3.0kg, using 10%-
30% ethyl alcohol is eluted, and eluent is abandoned, and using 90% ethanol elution, collects eluent, concentration using wet process or is done
Method silica gel loading carries out silica gel column chromatography, respectively obtains the monomers such as jateorrhizine, coptisine, palmatine, jamaicin；These
Monomer and combinations thereof has good inhibiting activity of acetylcholinesterase.
As a kind of specific preferred embodiment, prevention and treatment described in the embodiment of the present invention is obtained using extraction and isolated method
The method of the active material of dull-witted pharmaceutical composition is：Rhizoma Coptidis is provided, by taking 5Kg medicinal material as an example, is crushed after net system processing
At coarse powder, the ethyl alcohol of 50%-90% is added, impregnates 0-120min, is heated to reflux 2 times, it is 1.0-3.0 hours each；It is concentrated under reduced pressure,
Obtain thick paste 2.8kg；It is dried to obtain jateorrhizine, coptisine, palmatine, berberine composition 1.18kg；Composition solution
It is directly entered high-speed counter-current chromatograph, high speed adverse current chromatogram separation is carried out using chloroform-methanol-water system, obtains calumba
There is good acetylcholinesterase to inhibit to live for the monomers such as alkali, coptisine, palmatine, jamaicin, these monomers and combinations thereof
Property.
As a kind of specific preferred embodiment, prevention and treatment described in the embodiment of the present invention is obtained using extraction and isolated method
The method of the active material of dull-witted pharmaceutical composition is：Rhizoma Coptidis is provided, by taking 5Kg medicinal material as an example, is crushed after net system processing
At coarse powder, the hydrochloric acid of 0.1%-10% is adjusted between extracting solution PH1.5-6.0, extracts 1-6h, then adjusts pH value to 8-
14, precipitating is precipitated, it is dry, obtain jateorrhizine, coptisine, palmatine, berberine composition 0.88kg；By dry method or
Wet process loading carries out silica gel column chromatography, isolated containing monomers such as jateorrhizine, coptisine, palmatine, jamaicins.These
Monomer and combinations thereof has good inhibiting activity of acetylcholinesterase.
As a kind of specific preferred embodiment, prevention and treatment described in the embodiment of the present invention is obtained using extraction and isolated method
The method of the active material of dull-witted pharmaceutical composition is：Rhizoma Coptidis is provided, by taking 5Kg medicinal material as an example, is crushed after net system processing
At coarse powder, the ethyl alcohol of 50%-90% is added, impregnates 0-120min, is heated to reflux 2 times, it is 1.0-3.0 hours each, it is obtained by filtration
Extracting solution, extracting solution medicinal extract supercentrifuge is into centrifugation, and 10000 rpms to 18000 rpms of centrifugal speed；Extracting solution
Into ceramic membrane filter, filtered fluid is carrying out classification UF membrane, collects 100D to 5000D sections of component, then carry out reverse osmosis concentrated
Contracting, obtains jateorrhizine, coptisine, palmatine, berberine composition；Further use compound separation method, such as silica gel
Jateorrhizine, coptisine, palmatine, jamaicin etc. is made in the methods of post separation, high speed adverse current chromatogram, preparation solution phase respectively
Monomer.These monomers and combinations thereof have good inhibiting activity of acetylcholinesterase.
It is illustrated combined with specific embodiments below.
Embodiment 1
The analysis of activated monomer acetylcholine esterase active
Sample AChE inhibitory activity is measured using improved Ellman method, sample is selected from jateorrhizine, coptisine, barberry
Composition, the galanthamine of alkali, palmatine and four formation.Activity determination specific analytical method is as follows：
Using acetylthiocholine iodide as AChE substrate, Substrate hydrolysis is generated thio gallbladder by enzyme under conditions of pH8.0
Alkali, color developing agent DTNB reaction of the thiocholine of formation rapidly and in solution, generates the 5- sulfydryl -2- nitrobenzoic acid of yellow
Salt has absorption maximum in 410nm or so.When enzymatic activity is inhibited by tested sample part, enzyme hydrolysis iodate thioacetyl
The decline of gallbladder ability, the reduction of product thiocholine amount, the yellow substance reduction generated with color developing agent, absorbance value and test sample
AChE inhibitory activity has inverting linear relationship.Precision weighs each dry extract, and appropriate 20% EtOH Sonicate, which is added, to be made to dissolve, fixed
Hold, is each configured to 0.005ug/ml, 0.01ug/ml, 0.05ug/ml, 0.10ug/ml, 0.40ug/ml, 2ug/ml, 40ug/
The sample solution of ml；96 orifice plates are taken, sample sets, sample copy bottom group, positive control complete inhibition group and blank group are respectively set, often
Group respectively according to the following table 1 be added buffer, test solution, complete inhibition group (more piperazines how neat, galanthamine reference substance) solution,
AchE solution (specific sample-adding amount is shown in Table 1), cultivates 10min at a temperature of 4 DEG C；Using microplate reader measurement each sample at 405nm
Absorbance, record related data, according to following equation calculate inhibiting rate.IC50. is calculated using Graphpadprism5.0
Table 1
Testing result is as shown in table 2, wherein the composition be simultaneously containing jateorrhizine, coptisine, palmatine,
The composition of jamaicin, and the mass percentage of active material is 10% in the composition.
Table 2
The results show that jateorrhizine, coptisine, palmatine, jamaicin monomer component and combinations thereof, all have good
Acetylcholine esterase inhibition activity, and with currently used for treat AD chemicals compared with, the composition and its monomer component
With good acetylcholine esterase inhibition activity, there is preferable Development volue and application prospect.The especially embodiment of the present invention
The bioactivity of jateorrhizine, acetylcholine esterase inhibition is significant, hence it is evident that is higher than galanthamine.Even jateorrhizine,
Coptisine, palmatine, jamaicin mass percentage be 10% composition, the bioactivity of acetylcholine esterase inhibition
Also above galanthamine.
Embodiment 2
Experiment in vivo：AD rat model cognitive behavior is studied
Morris water maze laboratory, including the test of learning training, orientation navigation will be carried out after SD rat adaptive feeding 3 days
Qualified healthy normal rat 70 are screened in two parts, and it is anti-to be randomly divided into AD model group, sham-operation group, Normal group, Africa
Own alkali (high and low dose), the composition (high and low dose) containing jateorrhizine (including coptisine, palmatine, barberry alkaline constituents)
Group, every group each 10.A β is injected by bilateral hippocampus25-35It shares subcutaneous injection D- galactolipin and establishes AD pathological model, sham-operation
For group rat in addition to the ACSF for injecting 1 μ l in hippocampus, remaining processing is identical as AD model group.Before and after rat operation conventinal breeding in
Barrier environment.High dose group gives 10% composition by 10ml/kg weight stomach-filling, and low dose group then gives 2.5% composition.AD
The physiological saline of same volume is given in model group, sham-operation group and normal rats stomach-filling.Daily gastric infusion 1 time, totally 30 days.It removes
The daily the nape of the neck of normal rats is subcutaneously injected outside 0.9% physiological saline 0.6ml/kg, remaining each group rat is in the nape of the neck skin
Lower injection same volume 25%D- galactose solution 150mg/ (kg.d), continuous injection 50 days.
Start respectively within groups of animals the 26th day after operation carry out Morris water maze laboratory, including learning training experiment,
Two part of orientation navigation experiment.Computer is run, is tested after setup parameter.Rat is recorded in learning training to arrive in pond
Time and swimming distance up to security platform；The distance of rat orientation navigation is recorded in orientation navigation test and escapes latent time
(ST).After carrying out test of normality and homogeneity test of variance to all data, different statistical methods are selected as the case may be.
All data are handled with SPSS13.0 statistical analysis software, and significance level takes α=0.05 (bilateral), and P < 0.05 has for difference
Statistical significance.
The result shows that：AD model group rats reach the security platform time and more normal group of distance, sham-operation group dramatically increase,
Bilateral hippocampus is prompted to inject A β25-35It shares subcutaneous injection D- galactolipin and successfully manufactures the success of AD rat model.
Treatment group rat reaches the security platform time and distance is obviously shortened compared with AD model group rats, shows jateorrhizine
Group and the composition group for containing jateorrhizine (including coptisine, palmatine, barberry alkaline constituents), can improve AD rat
The ability of learning and memory that ability of learning and memory, especially jateorrhizine monomer can significantly improve AD rat.
Embodiment 3
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight：
The preparation method of the drug is：Above-mentioned supplementary material component is sufficiently mixed, it is straight using wet granulation or powder
Pressed disc method is connect, is made 100, tablet；Or filling capsule 100.
Embodiment 4
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight：
The preparation method of the drug is：Above-mentioned supplementary material component is sufficiently mixed, nanometer is modulated into using water for injection
Emulsion 1000ml.
Embodiment 5
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight：
Jateorrhizine 250mg
Borneol 10mg
PEG6000 4740mg
The preparation method of the drug is：Above-mentioned raw materials component is sufficiently mixed, is made dripping pill, 100.
Embodiment 6
A kind of big health-oriented products that prevention and treatment is dull-witted, the following raw material components including following parts by weight：
Jateorrhizine 250mg
Appropriate soybean oil
The preparation method of the big health-oriented products is：Above-mentioned supplementary material component is sufficiently mixed, using gelatin, glycerol, water
Appropriate configuration soft capsule peel, prepares soft capsule using pressing.
Embodiment 7
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight, wherein the active constituent group
Conjunction object is jateorrhizine, coptisine, palmatine, jamaicin.
The preparation method of the drug is：Above-mentioned supplementary material component is sufficiently mixed, it is straight using wet granulation or powder
Pressed disc method is connect, is made 100, tablet；Or filling capsule 100.
Embodiment 8
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight, wherein the active constituent group
Conjunction object is jateorrhizine, coptisine, palmatine, jamaicin.
The preparation method of the drug is：Above-mentioned supplementary material component is sufficiently mixed, micro emulsion is modulated into using water for injection
Agent 1000ml.
Embodiment 9
A kind of drug that prevention and treatment is dull-witted, the following raw material components including following parts by weight, wherein the active constituent group
Conjunction object is jateorrhizine, coptisine, palmatine, jamaicin.
Active ingredient compositions 250mg
Borneol 10mg
PEG6000 4740mg
The preparation method of the drug is：Above-mentioned raw materials component is sufficiently mixed, is made dripping pill, 100.
Embodiment 10
A kind of big health-oriented products that prevention and treatment is dull-witted, the following raw material components including following parts by weight, wherein the activity
Component composition is jateorrhizine, coptisine, palmatine, jamaicin.
Active ingredient compositions 250mg
Appropriate soybean oil
The preparation method of the big health-oriented products is：Above-mentioned supplementary material component is sufficiently mixed, using gelatin, glycerol, water
Appropriate configuration soft capsule peel, prepares soft capsule using pressing.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (9)
1. the drug or improvement of jateorrhizine or jateorrhizine pharmaceutically acceptable salt in preparation senile dementia prevention and cure
Application in the big health-oriented products of learning and memory class.
2. a kind of drug of senile dementia prevention and cure improves the big health-oriented products of learning and memory class, which is characterized in that the drug
Or big health-oriented products include the active material of acetylcholine esterase inhibition activity, the active material include jateorrhizine and/
Or jateorrhizine pharmaceutically acceptable salt.
3. the drug of senile dementia prevention and cure as claimed in claim 2 improves the big health-oriented products of learning and memory class, feature
It is, is the jateorrhizine and/or jateorrhizine medicine in terms of 100% by the total weight of the drug or big health-oriented products
The weight percentage of acceptable salt is 0.05%-100% on.
4. the drug of senile dementia prevention and cure as claimed in claim 2 improves the big health-oriented products of learning and memory class, feature
It is, is in terms of 100% by the total weight of the active material, the jateorrhizine and/or jateorrhizine can pharmaceutically connect
The weight percentage for the salt received is 0.5%-100%.
5. the drug of senile dementia prevention and cure as claimed in claim 2 improves the big health-oriented products of learning and memory class, feature
It is, as drug in use, the effective dose of the jateorrhizine and/or jateorrhizine pharmaceutically acceptable salt is
5mg-3000mg/ days.
6. the drug of senile dementia prevention and cure as claimed in claim 2 improves the big health-oriented products of learning and memory class, feature
It is, the jateorrhizine pharmaceutically acceptable salt is selected from jateorrhizine hydrochloride, jateorrhizine citrate, non-
At least one of continent root of fangji alkali phosphate, calumba alkali sulfate, jateorrhizine disulfate.
7. the big health of drug or improvement learning and memory class such as the described in any item senile dementia prevention and cures of claim 2-6 produces
Product, which is characterized in that the drug or big health-oriented products further include pharmaceutically acceptable auxiliary material.
8. the big health of drug or improvement learning and memory class such as the described in any item senile dementia prevention and cures of claim 2-6 produces
Product, which is characterized in that the dosage form of the drug or big health-oriented products is mixture capsule, tablet, pill, powder, pulvis, cream
Agent, gelling agent, dripping pill, sustained-release preparation, any dosage form in liposome.
9. the drug of senile dementia prevention and cure as claimed in claim 8 improves the big health-oriented products of learning and memory class, feature
It is, the tablet includes dispersible tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810461753.0A CN108926561A (en) | 2018-05-15 | 2018-05-15 | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810461753.0A CN108926561A (en) | 2018-05-15 | 2018-05-15 | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108926561A true CN108926561A (en) | 2018-12-04 |
Family
ID=64448869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810461753.0A Pending CN108926561A (en) | 2018-05-15 | 2018-05-15 | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108926561A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110101698A (en) * | 2019-06-04 | 2019-08-09 | 澳门大学 | The application of jateorrhizine and pharmaceutical preparation |
| CN110179859A (en) * | 2019-06-27 | 2019-08-30 | 香港科技大学深圳研究院 | The application of Radix Stephaniae Tetrandrae extract and fangchinoline in pharmacy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225023A (en) * | 2013-06-13 | 2014-12-24 | 香港浸会大学 | Composition comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases |
-
2018
- 2018-05-15 CN CN201810461753.0A patent/CN108926561A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225023A (en) * | 2013-06-13 | 2014-12-24 | 香港浸会大学 | Composition comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases |
Non-Patent Citations (2)
| Title |
|---|
| HENGQIANG ZHAO等: "An in vitro AChE inhibition assay combined with UF-HPLC-ESI-Q-TOF/MS approach for screening and characterizing of AChE inhibitors from roots of Coptis chinensis Franch", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
| YING HU等: "In vitro studies on the multi-target anti-Alzheimer activities of berberine-like alkaloids from Coptidis Rhizoma", 《JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110101698A (en) * | 2019-06-04 | 2019-08-09 | 澳门大学 | The application of jateorrhizine and pharmaceutical preparation |
| CN110179859A (en) * | 2019-06-27 | 2019-08-30 | 香港科技大学深圳研究院 | The application of Radix Stephaniae Tetrandrae extract and fangchinoline in pharmacy |
| CN110179859B (en) * | 2019-06-27 | 2021-09-24 | 香港科技大学深圳研究院 | Application of radix Stephaniae Tetrandrae extract and fangchinoline in pharmacy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100566714C (en) | A kind of Herba Lycopodii serrati composition and method of making the same that contains huperzine A, second composite parts | |
| CN103393736B (en) | A kind of for pharmaceutical composition treating Alzheimer and its production and use | |
| CN104225524B (en) | Purposes of the snakegourd Guizhi decoction in the medicine for preparing treatment or/and prevention cognition dysfunction | |
| CN108926561A (en) | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product | |
| CN102727619A (en) | Medicinal composition treating fatty liver and preparations thereof | |
| JP7287937B2 (en) | Composition used for regulation of intestinal permeability and/or treatment and/or prevention of intestinal wall leakage-related diseases | |
| CN1931874B (en) | Preparation process, medicine preparation and medicinal use of ginseng glycopeptide | |
| CN102692477B (en) | Medicinal composition used for treating fatty liver and quality detection method thereof | |
| CN102827001A (en) | Ilex kudingcha C.J.Tseng extract | |
| CN111714511A (en) | Codonopsis pilosula oligosaccharide composition and application thereof in preparation of preparation for preventing and treating senile dementia | |
| CN101317867B (en) | Application of standard extract of pseudo-ginseng in preparing medicament for preventing and controlling senile dementia | |
| CN102188471A (en) | Pharmaceutical composition for treating Alzheimer disease symptom and its preparation method | |
| KR20170062781A (en) | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN100382807C (en) | Natural medicine composition for preventing and treating metabolic syndrome | |
| JP2005194256A (en) | Hepatic disease-treating medicinal composition and method for producing the same | |
| CN107951838A (en) | Application of the asarone Submicron Emulsion in Alzheimer disease is prevented and treated | |
| CN100406003C (en) | Dripping pills of abastard speedwell and its preparation process | |
| CN103565761B (en) | Galanthamine hydrobromide orally disintegrating tablet | |
| CN106309546A (en) | Extract for treating diabetic nephropathy | |
| CN106728570A (en) | A kind of pharmaceutical composition for preventing and treating diabetes cognitive disorder and preparation method thereof | |
| CN108371712A (en) | Caffeine combines the purposes prepared in AD drugs with PPAR gamma agonists | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator | |
| CN105687225B (en) | A kind of pharmaceutical composition for treating irritable bowel syndrome and its preparation method and application | |
| TWI807164B (en) | Pharmaceutical composition and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wu Zhengzhi Inventor after: Zeng Yongchang Inventor after: Liang Shaoyu Inventor after: Wu Junhong Inventor after: Li Xinping Inventor before: Zeng Yongchang Inventor before: Wu Zhengzhi Inventor before: Liang Shaoyu Inventor before: Wu Junhong Inventor before: Li Xinping |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181204 |
|
| RJ01 | Rejection of invention patent application after publication |